Net Loss per Share

6 Months Ended

Jun. 30, 2018

Basic and diluted net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. was calculated as follows:



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Numerator:
Net loss	$	(39,269	)	$	(38,440	)	$	(124,731	)	$	(57,193	)
Accretion of beneficial conversion feature on Series A preferred shares	—			(8,006		)	—			(12,006		)
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$	(39,269	)	$	(46,446	)	$	(124,731	)	$	(69,199	)
Denominator:
Weighted average common shares outstanding—basic and diluted	38,942,545			26,038,192			37,873,755			19,563,525
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted	$	(1.01	)	$	(1.78	)	$	(3.29	)	$	(3.54	)

The Company’s potential dilutive securities, which include stock options and warrants to purchase common shares, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders of the Company is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:



	Three Months Ended June 30,		Six Months Ended June 30,
	2018	2017	2018	2017
Options to purchase common shares	6,019,570	4,717,870	6,019,570	3,247,500
Warrants to purchase common shares	221,751	821,751	221,751	600,000
	6,241,321	5,539,621	6,241,321	3,847,500